DARVON-N W/ ASA
LOE Approachingaspirin; propoxyphene napsylate
NDAORALCAPSULE
Approved
Sep 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DARVON-N W/ ASA is an oral capsule combination of propoxyphene napsylate (opioid analgesic) and aspirin (NSAID) approved in 1971 for pain management. It provides moderate analgesia through dual mechanisms: opioid receptor agonism and COX inhibition. This product is now approaching loss of exclusivity and represents a legacy oral analgesic in a crowded pain market.
LOE Approaching
With LOE approaching and minimal recent commercial activity, brand teams are likely small and focused on managed decline or generic transition support.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DARVON-N W/ ASA offers limited career growth given the product's LOE-approaching status and minimal linked job openings (0 current opportunities). This role is best suited for professionals seeking managed-decline portfolio experience or generic transition expertise rather than launch or growth acceleration.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.